Petosemtamab

iStock, Ekaterina Chergik Only one clinical-stage asset from the ProfoundBio acquisition remains in development: The antibody-drug conjugate Rina-S, in late-stage studies for ovarian and endometrial cancer. Genmab has scrapped another antibody-drug conjugate picked up in its $1.8 billion acquisition of ProfoundBio last year, continuing the pruning of that company’s molecules. The asset, dubbed GEN1160, was in a Phase I/II study assessing its safety and efficacy for blood cancers and solid tumors. The trial was cut “due to slow enrollment,” according to an update to a federal clinical trials database. Confirming the move to Fierce Biotech , a Genmab spokesperson added that GEN1160 is being shelved “in line with our portfolio prioritization strategy.” “This approach ensures we focus our resources on developing innovative antibody medicines with the greatest potential to make a meaningful impact for patients,” the spokesperson said. Monday’s news comes after Genmab in September discontinued the development of GEN1107, another antibody-drug conjugate (ADC) that was in Phase I/II development, but this time for advanced solid tumors, including ovarian, endometrial and triple-negative breast cancer. According to its own Clinical Trials.gov page , GEN1107 was abandoned because its “overall benefit-risk pro longer supports continuation.” GEN1160 and GEN1107 are two of the three clinical-stage cancer assets obtained by Genmab in its $1.8 billion acquisition of ProfoundBio in April 2024. The remaining clinical molecule from that deal, rinatabart sesutecan (Rina-S), the centerpiece of the acquisition, remains in development. Rina-S is in late-stage development for platinum-resistant ovarian cancer and endometrial cancer. The drug had a readout last month in endometrial cancer at the 2025 meeting of the European Society for Medical Oncology. In the Phase I/II RAINFOL-01 study, Rina-S, which was dosed every 3 weeks, elicited a 50% confirmed objective response rate over a median follow-up of 1 year. RAINFOL-01 enrolled heavily pretreated patients with endometrial cancer whose disease had progressed even after platinum-based chemotherapy and immune checkpoint inhibition. The study also documented two complete responses. Meanwhile, in March, Genmab released Phase I/II data for Rina-S in ovarian cancer, touting a confirmed objective response rate of 55.6% in heavily pretreated patients, with median duration of response not yet reached. Elsewhere in its oncology push, Genmab in September acquired rising cancer star Merus for $8 billion. The buyout, which represented a 41% premium to Merus’ closing price the day before the deal was announced, will give Genmab the bispecific antibody petosemtamab that binds both EGFR and LGR5 markers. In May, petosemtamab plus Keytruda treatment resulted in a 79% overall survival rate at 12 months in a Phase II study of head-and-neck squamous cell carcinoma. The overall response rate was 63%.

GEN1160 joins another spoil from the ProfoundBio buy, GEN1107, on Genmab’s scrap heap.\n Genmab has shed another antibody-drug conjugate from its April 2024 acquisition of ProfoundBio. The Danish pharma has dropped development of GEN1160, a company spokesperson confirmed to Fierce Biotech, halting a phase 1/2 trial of the asset.“GEN1160 has been discontinued due to low enrollment in the clinical trial and in line with our portfolio prioritization strategy,” the Genmab spokesperson said. “This approach ensures we focus our resources on developing innovative antibody medicines with the greatest potential to make a meaningful impact for patients.”The trial had been testing GEN1160 in patients with renal cell carcinoma, nasopharyngeal carcinoma and non-Hodgkin lymphoma.GEN1160 joins another spoil from the ProfoundBio buy, GEN1107, on Genmab’s scrap heap. The drugmaker scuttled its solid tumor candidate, GEN1107, in September after a phase 1/2 trial revealed a subpar risk-benefit profile.Genmab is still pursuing rinatabart sesutecan (Rina-S), ProfoundBio’s star asset, in ovarian and endometrial cancers, the spokesperson said, along with GEN1286 in solid tumors. The pharma is currently enrolling patients with advanced solid tumors in a phase 1/2 trial for GEN1286, formerly known as PRO1286. Rina-S is a potential competitor to AbbVie’s Elahere, but the Chicago pharma has taken legal steps to interrupt Genmab’s ADC development. AbbVie alleged in a March lawsuit that ProfoundBio built its ADC tech on stolen trade secrets from a former AbbVie employee.Genmab said it would “vigorously defend” itself against AbbVie’s claims, and noted that numerous other companies—such as Adcentrx, Alvotech, BeiGene and Revance—have come under fire from the American pharma in similar cases.In May, Rina-S beat analyst expectations with a 50% unconfirmed response rate in advanced endometrial cancer, fueling a phase 3 push in the indication that is set to begin this month, according to clinicaltrials.gov. In October, Genmab released further phase 1/2 data showing Rina-S achieved a 50% objective response rate, including two patients whose cancer completely disappeared.Though it is winnowing down its assets from ProfoundBio, Genmab is still building up its cancer pipeline overall. At the end of September, Genmab shelled out a hefty $8 billion for Netherlands-based biotech Merus and its bispecific antibody, petosemtamab.The antibody previously notched a 79% 12-month survival rate in a phase 2 trial of patients with PD-L1–positive recurrent or metastatic head and neck squamous cell carcinoma, with analysts hailing its “best-in-disease profile.”